Journal
CURRENT ONCOLOGY REPORTS
Volume 19, Issue 1, Pages -Publisher
SPRINGER
DOI: 10.1007/s11912-017-0562-0
Keywords
Cancer; Cachexia; Quality of life; Muscle loss; Body weight; Nutrition; Inflammation; Appetite; Ghrelin; Exercise; Therapy; Multimodal; Clinical management
Categories
Funding
- U.S. Dept. of Veterans Affairs (MERIT) [I01BX002807, I01 CX000174]
- NIH [AG040583, AR067319, CA185349]
Ask authors/readers for more resources
Cachexia is a metabolic syndrome driven by inflammation and characterized by loss of muscle with or without loss of fat mass. In cancer cachexia, the tumor burden and host response induce increased inflammation, decreased anabolic tone, and suppressed appetite leading to the clinical presentation of reduced body weight and quality of life (QOL). There is no approved treatment for cancer cachexia, and commonly used nutritional and anti-inflammatory strategies alone have proven ineffective for management of symptoms. Several other pharmacological agents are currently in development and have shown promise as a clinical strategy in early-phase trials. Recently, it has been proposed that multimodal strategies, with an anabolic focus, initiated early in the disease/treatment progression may provide the most therapeutic potential for symptom management. Here we review the data from recent clinical trials in cancer cachexia including pharmacological, exercise, and nutritional interventions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available